Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Brückmann M, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Among authors: hooi ls. J Am Soc Nephrol. 2024 Feb 1;35(2):202-215. doi: 10.1681/ASN.0000000000000271. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082486 Free PMC article. Clinical Trial.
Effects of lowering LDL cholesterol on progression of kidney disease.
Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG, Baigent C, Landray MJ; SHARP Collaborative Group; SHARP Collaborative Group. Haynes R, et al. J Am Soc Nephrol. 2014 Aug;25(8):1825-33. doi: 10.1681/ASN.2013090965. Epub 2014 May 1. J Am Soc Nephrol. 2014. PMID: 24790178 Free PMC article. Clinical Trial.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. Baigent C, et al. Among authors: hooi ls. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12. Lancet. 2011. PMID: 21663949 Free PMC article. Clinical Trial.
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
Herrington W, Emberson J, Staplin N, Blackwell L, Fellström B, Walker R, Levin A, Hooi LS, Massy ZA, Tesar V, Reith C, Haynes R, Baigent C, Landray MJ; SHARP Investigators. Herrington W, et al. Among authors: hooi ls. Clin J Am Soc Nephrol. 2014 May;9(5):914-9. doi: 10.2215/CJN.10371013. Epub 2014 Mar 13. Clin J Am Soc Nephrol. 2014. PMID: 24626433 Free PMC article. Clinical Trial.
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM; IMPROVE-CKD Trial Investigators. Toussaint ND, et al. Among authors: hooi ls. J Am Soc Nephrol. 2020 Nov;31(11):2653-2666. doi: 10.1681/ASN.2020040411. Epub 2020 Sep 11. J Am Soc Nephrol. 2020. PMID: 32917784 Free PMC article. Clinical Trial.
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Wong MG, Lv J, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Reich HN, Cattran D, Glassock R, Levin A, Jardine MJ, Wheeler DC, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V; TESTING Study Group. Wong MG, et al. Among authors: hooi ls. Am J Nephrol. 2021;52(10-11):827-836. doi: 10.1159/000519812. Epub 2021 Nov 3. Am J Nephrol. 2021. PMID: 34731857 Free PMC article.
Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study.
Saminathan TA, Hooi LS, Mohd Yusoff MF, Ong LM, Bavanandan S, Rodzlan Hasani WS, Tan EZZ, Wong I, Rifin HM, Robert TG, Ismail H, Wong NI, Ahmad G, Ambak R, Othman F, Abd Hamid HA, Aris T. Saminathan TA, et al. Among authors: hooi ls. BMC Nephrol. 2020 Aug 14;21(1):344. doi: 10.1186/s12882-020-01966-8. BMC Nephrol. 2020. PMID: 32795256 Free PMC article.
74 results